# Reven Pharmaceuticals

> Privately held, clinical-stage biopharmaceutical company founded in 1999 and headquartered in
> Broomfield, Colorado. Reven develops medicines from its proprietary RJX Technology platform - a
> patented, first-in-class intravenous composition of anti-oxidant and anti-inflammatory ingredients -
> with programs in sepsis, multi-system inflammation, cytokine release syndrome, ARDS, and vascular,
> oncology, CNS and ocular indications. Lead candidate Rejuveinix (RJX) completed a double-blind,
> placebo-controlled Phase 1 dose-escalation study in healthy volunteers and received FDA clearance of an
> Investigational New Drug application for the treatment of COVID-19.

## API surface

Reven Pharmaceuticals publishes **no public API**. As of 2026-08-26 there is no developer portal, no API
reference, no OpenAPI/AsyncAPI/GraphQL/gRPC/WSDL contract, no SDK or client package in any public
registry, no MCP server, and no A2A agent card. Every canonical discovery path on reven.com
(/openapi.json, /swagger.json, /api-docs, /graphql, /llms.txt, and the /.well-known/ set) returns 404.

The only machine-readable endpoint on the domain is https://reven.com/wp-json/, the default WordPress
REST API exposed by the corporate website's CMS. Its 228 routes are entirely WordPress core plus
installed plugins (Yoast, Elementor, Wordfence, LiteSpeed, Akismet, Formidable); it describes the
marketing site's content, not a Reven product, and is not treated here as a published company API.

## Company

- [Overview](https://reven.com/company/): who Reven is, founding, and mission
- [RJX Technology](https://reven.com/rjx/): the platform behind every program
- [Pipeline](https://reven.com/pipeline/): programs and their stage
- [Modalities](https://reven.com/modalities/): the families of potential modalities
- [Research & Development](https://reven.com/research/)
- [Products](https://reven.com/products/)
- [Clinical Trials](https://reven.com/clinical-trials/)
- [Expanded Access](https://reven.com/expanded-access/): compassionate-use program
- [Leadership](https://reven.com/leadership/)
- [Social Accountability](https://reven.com/social/)

## News

- [News](https://reven.com/news/): company press releases
- [Industry News](https://reven.com/industrynews/)
- [RSS feed](https://reven.com/feed/)

## Contact

- [Contact Us](https://reven.com/contact-us/)
- [Join Reven](https://reven.com/join-reven/): careers
- [Investor Portal](https://reven.com/investor-portal/): login-gated, investors only
- [LinkedIn](https://www.linkedin.com/company/revenpharmaceuticals)

## Optional

- [Secondary-market listing](https://forgeglobal.com/reven-pharmaceuticals_stock/) on Forge Global
- [API Evangelist profile](https://apis.io/provider/reven-pharmaceuticals/)

---
generated: 2026-08-26
method: generated
source: apis.yml + reven.com site probe (no provider-published /llms.txt; https://reven.com/llms.txt -> 404)